BioBlocks has been awarded a research and innovation grant from the EU’s Horizon 2020 program for its Leap-to-Lead platform, which aims to transform the process of early-stage drug discovery. This program seeks to drive economic growth by providing funding to companies engaged in world-class science. The grant is one of the most competitive in this program, with a selection rate between 4 and 8 percent. Only the most innovative projects with high market potential are selected.
BioBlocks is a pioneering medicinal chemistry research organization focused on drug discovery from initial lead discovery to development candidates. The company has a highly educated, international team with over 100 years of combined medicinal chemistry experience. BioBlocks has locations in San Diego, CA, and Budapest, HU.
The BioBlocks Leap-to-Lead™ platform radically improves the generation and optimization of drug candidate molecules or "leads.” This approach is a cost-effective alternative to standard drug discovery methods such as high-throughput screening (HTS).
The process starts with the BioBlocks Comprehensive Fragment Library (CFL) which the company uses with its partners to find high-quality initial hits. These hits are converted into proprietary leads through the analog-generating Syntheverse™ technology. This process creates strategic value for partners of BioBlocks by providing novel, high quality leads for their targets.
The funding from the Horizon 2020 grant will provide support as BioBlocks pursues its goals of expanding the Leap-to-Lead™ platform and bringing it to the drug discovery market.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 827248.